Title:Current Treatment for Cervical Cancer: An Update
Volume: 20
Issue: 15
Author(s): Sombeer Sharma, Aakash Deep*Arun K. Sharma*
Affiliation:
- Department of Pharmaceutical Sciences, Chaudhary Bansi Lal University, Bhiwani-127021, Haryana,India
- Department of Pharmacology, Amity Institute of Pharmacy, Amity University, Haryana-122413,India
Keywords:
Cervical cancer, clinical trial, pipeline drug for cervical cancer, pharmacokinetics, quality of life, molecular biology.
Abstract: Cervical cancer is the leading gynecologic health problem which is considered as the 4th most widespread
tumour in women. The prevalence of this fatal ailment is emerging gradually across the globe as about
18.1 million new cancer cases have been reported in 2018. The predominance of cervical cancer has been significantly
found in low and middle-income countries as cervical cancer ranks fourth for both incidence and
mortality, conversely, there are no effective screening systems available. This mortal state is certainly influenced
by exposure of human papillomavirus, dysregulation of caspase enzyme, elevated expression of Inhibitor
Apoptotic Protein (IAP), overexpression of Vascular Endothelial Growth Factors (VEGF), active/passive smoking,
and dysfunction of the immune system. Generally, the clinical trial on pipeline drugs leads to the development
of some promising new therapies that are more effective than standard approaches and often unavailable
outside of the clinical setting. Indeed, several biological interventions that can modulate the pathological cascade
of cervical cancer are still under investigation. Thus, there is a need to further summarise the promising
therapies for cervical cancer as we have accomplished in HER2-positive breast cancer by targeting HER2 therapies
and immune checkpoint inhibitors in melanoma. The present report revealed the pharmacokinetic/
pharmacodynamics aspects of various pipeline drugs that are promising for the treatment of cervical cancer.
Moreover, the study revealed the possible mechanism, adverse drug reaction, combined therapy and pleiotropic
action of these under investigational drugs, which can further improve the therapeutic efficacy and restrict
the imaginable harmful effects.
